These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3118265)

  • 41. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
    Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
    Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.
    Canavese C; Pacitti A; Segoloni G; Thea A; D'Amicone M; Stratta P; Rossi P; Sabbioni E; Pietra R; Constantini S
    J Trace Elem Electrolytes Health Dis; 1989 Mar; 3(1):17-23. PubMed ID: 2535315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
    Allain P; Chaleil D; Mauras Y; Beaudeau G; Varin MC; Poignet JL; Ciancioni C; Ang KS; Cam G; Simon P
    Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
    Yaqoob M; Ahmad R; McClelland P; Shivakumar KA; Sallomi DF; Fahal IH; Roberts NB; Helliwell T
    Postgrad Med J; 1993 Feb; 69(808):124-8. PubMed ID: 8506193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron removal by desferrioxamine during haemodialysis: in vitro studies.
    Müller-Wiefel DE; Vorderbrügge U; Schärer K
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():377-81. PubMed ID: 3991526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
    Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
    Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients.
    Janssen MJ; van Boven WP
    Pharm World Sci; 1996 Oct; 18(5):187-91. PubMed ID: 8933580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
    Casati S; Castelnovo C; Campise M; Ponticelli C
    Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Aluminum in chronic renal failure].
    Głuszek J; Adamczak H
    Rocz Panstw Zakl Hig; 1993; 44(1):43-8. PubMed ID: 8235341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
    Verbeelen D; Smeyers-Verbeke J; van Hooff I; de Roy G
    J Trace Elem Electrolytes Health Dis; 1988 Jun; 2(2):67-72. PubMed ID: 2980801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion.
    Ciancioni C; Poignet JL; Naret C; Delons S; Mauras Y; Allain P; Man NK
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():469-73. PubMed ID: 3991542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
    Andriani M; Nordio M; Saporiti E
    Nephron; 1996; 72(2):218-24. PubMed ID: 8684530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.